Scopus BioPharma Inc.
OperatingBiotech · New York, NY
Financials
FY2018–FY2022 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Cap table
Share counts as of Jan 26, 2021| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Common Stock | 14,577,597 | 1 | 100.0% | — |
Shares outstanding over timein today's share terms
Changes in named holdersshares in today's terms · % of all shares at the time
- David A. Buckel49K May 2022 → 82K Apr 2023
- David Weild IV43K May 2022 → 76K Apr 2023
- Ira Scott Greenspan1.5M (10.8%) May 2020 → 8.7M May 2022 → 1.5M Apr 2023
- Joshua R. Lamstein1.5M (10.5%) May 2020 → 8.6M May 2022 → 1.5M Apr 2023
- Robert J. Gibson212K (1.52%) May 2020 → 6.2M May 2022 → 212K Apr 2023
- Ashish P. Sanghrajka67K (0.48%) May 2020 → 517K May 2022
Principal holders% as the filing states it, Apr 28, 2023
- Morris C. Laster, M.D.6,006,000 Common Stock15.1%of company
- Armistice Capital, LLC2,100,000 Common Stock5%of company
- Ira Scott Greenspan1,520,424 Common Stock3.8%of company
- Joshua R. Lamstein1,469,997 Common Stock3.7%of company
- Robert J. Gibson212,352 Common Stock0.5%of company
- David Weild IV76,431 Common Stock0.2%of company
- David A. Buckel82,372 Common Stock0.2%of company
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
11 peopleShow 2 more peopleShow fewer
Names and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.
SEC filings
View all 49 filings on EDGAR- Form 1-ZFeb 9, 20240001104659-24-013432EDGAR
- Form 10-QAug 11, 20230001410578-23-001787EDGAR
- Form 10-QMay 12, 20230001410578-23-001110EDGAR
- Form 10-K/AApr 28, 20230001104659-23-053138EDGAR
- Form 10-KApr 14, 20230001410578-23-000666EDGAR
- Form 10-QNov 21, 20220001410578-22-003519EDGAR
- Form 10-QAug 15, 20220001410578-22-002634EDGAR
- Form 10-QMay 19, 20220001410578-22-001792EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.